Michel Orsinger held the position of Worldwide Chairman DePuy Synthes Companies at Johnson & Johnson ("J&J") from 2012 to 2015. He was also a member of J&J's Global Management Team. Michel Orsinger joined Johnson & Johnson following the sale of Synthes Inc. for $20 billion, the largest acquisition ever realized by Johnson & Johnson. Subsequently, Michel Orsinger established the world wide’s largest and most comprehensive orthopedic company. Prior to his leadership role at J&J, Mr Orsinger was COO and CEO of Synthes Inc for eight years, and spent eleven years with Novartis. Today, Michel Orsinger is an investor as well as board member of several start-up companies and an advisor to EQT. Moreover, he joined the Board of Takeda in 2016, the largest Japanese and Asian pharmaceutical company.  

Research on osteoarthritis, detailed study of Muscular system and Osteon system